Hideki Makinoshima
Overview
Explore the profile of Hideki Makinoshima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, et al.
Nature
. 2025 Feb;
639(8053):E5.
PMID: 39948434
No abstract available.
2.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, et al.
Nature
. 2025 Jan;
638(8049):225-236.
PMID: 39843734
Cancer cells in the tumour microenvironment use various mechanisms to evade the immune system, particularly T cell attack. For example, metabolic reprogramming in the tumour microenvironment and mitochondrial dysfunction in...
3.
Nakayama J, Tan L, Li Y, Goh B, Wang S, Makinoshima H, et al.
Elife
. 2024 Jul;
13.
PMID: 39082603
No abstract available.
4.
Nakasuka F, Hirayama A, Makinoshima H, Yano S, Soga T, Tabata S
FEBS Open Bio
. 2024 Jul;
14(9):1570-1583.
PMID: 39030877
Epithelial-to-mesenchymal transition (EMT) contributes to the poor prognosis of patients with cancer by promoting distant metastasis and anti-cancer drug resistance. Several distinct metabolic alterations have been identified as key EMT...
5.
Tabata S, Endo H, Makinoshima H, Soga T, Inoue M
Biochem Biophys Res Commun
. 2024 Apr;
714:149977.
PMID: 38663093
Malignant tumors are characterized by a hypoxic microenvironment, and metabolic reprogramming is necessary to ensure energy production and oxidative stress resistance. Although the microenvironmental properties of tumors vary under acute...
6.
Ohashi Y, Ooyama H, Makinoshima H, Takada T, Matsuo H, Ichida K
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397902
Gout results from monosodium urate deposition caused by hyperuricemia, but most individuals with hyperuricemia remain asymptomatic. The pathogenesis of gout remains uncertain. To identify potential biomarkers distinguishing gout from asymptomatic...
7.
Tabata S, Umemura S, Narita M, Udagawa H, Ishikawa T, Tsuboi M, et al.
Mol Cancer Res
. 2023 Sep;
22(1):82-93.
PMID: 37773022
Implications: SCLC tumors preferentially utilize either the de novo or salvage pathway in purine nucleotide biosynthesis, and HPRT1 has therapeutic implications in SCLC.
8.
Hiranuma K, Asami Y, Kato M, Murakami N, Shimada Y, Matsuda M, et al.
Cancer Med
. 2023 Aug;
12(17):17835-17848.
PMID: 37537783
Background: Although cervical cancer is often characterized as preventable, its incidence continues to increase in low- and middle-income countries, underscoring the need to develop novel therapeutics for this disease.This study...
9.
Nakayama J, Makinoshima H, Gong Z
Bio Protoc
. 2023 May;
13(10):e4673.
PMID: 37251091
Here, we present an in vivo drug screening protocol using a zebrafish model of metastasis for the identification of anti-metastatic drugs. A tamoxifen-controllable transgenic zebrafish line was established to serve...
10.
Nakayama J, Makinoshima H, Gong Z
Bio Protoc
. 2022 Oct;
12(19).
PMID: 36313195
Few models exist that allow for rapid and effective screening of anti-metastasis drugs. Here, we present a drug screening protocol utilizing gastrulation of zebrafish embryos for identification of anti-metastasis drugs....